Navigation Links
ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology
Date:2/9/2010

LEUVEN, Belgium, February 9 /PRNewswire-FirstCall/ --

- Paper Examines the Potential of Microplasmin to Improve the Treatment of a Range of Back of the Eye Diseases

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that the positive microplasmin Phase II trial results, evaluating the product's efficacy and safety in patients who require vitrectomy, have been published in the prestigious American Academy of Ophthalmology's Journal, Ophthalmology, the leading journal for the vitreoretinal community.

A paper entitled "A Placebo-Controlled Trial of Microplasmin Intravitreous Injection to Facilitate Posterior Vitreous Detachment Before Vitrectomy" has been published online ahead of print in Ophthalmology. This publication covers the Phase II trial (MIVI III) with microplasmin, with the objective of evaluating the efficacy and safety of intravitreal microplasmin in facilitating the separation of the vitreous from the retina. The separation of the vitreous from the retina is used to treat a range of back of the eye disorders and is achieved currently via a surgical procedure called a vitrectomy.

The paper showed that the highest dose of microplasmin (125microg) led to a greater likelihood of induction and progression of PVD than placebo injection. Moreover, patients in this dose group had a statistically significant improvement in visual acuity at the 35-day timepoint when compared to placebo. Also, the trial showed that patients receiving microplasmin were significantly more likely not to require vitrectomy surgery to resolve their underlying disease.

The results outlined in the article highlight that microplasmin could be a potential breakthrough for the treatment of certain patients suffering from vitreoretinal pathologic conditions related to vitreomacular adhesion. Vitreomacular adhesion is thought to play a key role in numerous back of the eye conditions such as macular hole formation, and some forms of macular edema. Vitreomacular adhesion is also associated with much poorer prognosis in certain major eye conditions, including diabetic retinopathy and Age-Related Macular Degeneration (AMD).

ThromboGenics is now conducting an extensive Phase III program with microplasmin, referred to as MIVI-TRUST (Microplasmin IntraVitreous Injection - Traction Release without Surgical Treatment), for the non-surgical resolution of focal vitreomacular adhesion. The patient enrollment for the two Phase III trials was completed in 2009 ahead of schedule. The first results from this Phase III program are due in Q2 2010.

For a full discussion of the results from the Phase II trial (MIVI III), please refer to the Ophthalmology article.[1] Further information is also included in the ThromboGenics press release dated 30 June, 2008 (see http://www.thrombogenics.com).

Steve Pakola, MD, Chief Medical Officer of ThromboGenics and co-author of the Ophthalmology paper, commented, "We are very pleased to have had these results with microplasmin published in such a prestigious journal. The Phase II trial data discussed in the paper demonstrate the exciting potential of microplasmin in treating a range of important back of the eye diseases. We very much look forward to announcing the first results from our Phase III program with microplasmin by mid 2010."

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

---------------------------------

[1] "A Placebo-Controlled Trial of Microplasmin Intravitreous Injection to Facilitate Posterior Vitreous Detachment Before Vitrectomy," Matthew S. Benz, MD, Kirk H. Packo, MD, Victor Gonzalez, MD, Stephen Pakola, MD, Donna Bezner, Julia A. Haller, MD, Steven D. Schwartz, MD, Ophthalmology, Abstract available at http://www.ophsource.org/periodicals/ophtha/article/S0161-6420( 09)01293-7/abstract

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

    For further information please contact:

    ThromboGenics
    Dr. Steve Pakola, CMO,
    Dr. Patrik De Haes, CEO,
    Tel: +1(212)201-0920,
    steve.pakola@thrombogenics.com ,
    Tel: +32-16-75-13-10 ,
    patrik.dehaes@thrombogenics.com;

    Citigate Dewe Rogerson
    Amber Bielecka/ David Dible/ Nina Enegren,
    Tel: +44(0)207-638-95-71,
    amber.bielecka@citigatedr.co.uk


SOURCE ThromboGenics NV


'/>"/>
SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ThromboGenics NV - Q3 2009 Business Update
2. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
3. ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
4. ThromboGenics NV Announces Business Update and Half Year Results 2009
5. ThromboGenics NV: Business Update
6. ThromboGenics Announces Business Update and 2008 Full Year Results
7. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
8. ThromboGenics N.V.: Business Update
9. ThromboGenics Announces Half Year Results 2008
10. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
11. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... June 28, 2017 Michael Zasloff , ... University School of Medicine, and Founder, Chairman and CEO ... study that has helped clarify the function of alpha-Synuclein ... other neurodegenerative diseases. Denise Barbut , MD, FRCP, ... was senior co-author of the study. Published ...
(Date:6/28/2017)... ... June 28, 2017 , ... ... three research projects accepted for presentation at the 33rd Annual Meeting of the ... – including some of the world’s top thought leaders in reproductive medicine – ...
(Date:6/28/2017)... and London, June 28, 2017 (PRWEB) , ... ... ... The latest release of Siemens’ STAR-CCM+® software for multiphysics computational fluid ... enable automated product design exploration and optimization. STAR-CCM+ version 12.04 introduces Design ...
(Date:6/28/2017)... NC (PRWEB) , ... June 28, 2017 , ... Studies ... might lead to an effective treatment for Parkinson’s disease. But what has not been ... should take place to gain the best results. , A new study coming out ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 8.8% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):